Loading patent…
AssigneesNational University of Singapore, DSO National Laboratories
InventorsPaul Anthony Macary, Ee Ping Evelyn Teoh, Brendon John Hanson, En Wei Teo, Angeline Pei Chiew Lim, Mah Lee Mary Ng, Shee Mei Lok, Petra Eveliina Kukkaro
Estimating the term…
Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.
A method of passive immunization comprising administration to a subject of an effective amount of an isolated neutralizing monoclonal antibody that specifically binds to a Dengue virus serotype 1 envelope (E) protein, wherein the neutralizing monoclonal antibody is a human antibody with broadly neutralizing activity that binds across two E proteins in a virus, wherein the binding across two E proteins comprises binding to DI and the hinge between DI and II on one E protein and DIII of a neighboring E protein, wherein the antibody or fragment thereof binds to amino acids T51, G159, T160, T165, P166, Q167, E172, 1173, and T275 of SEQ ID NO:33 in DI, amino acids N52 and G274 of SEQ ID NO:33 in DII, and K310 of SEQ ID NO:33 in DIII, and
A method of treating a Dengue virus infection comprising administration to a subject of an amount of an isolated neutralizing monoclonal antibody that specifically binds to a Dengue virus serotype 1 envelope (E) protein and is effective to reduce or prevent the Dengue virus infection, wherein the neutralizing monoclonal antibody is a human antibody with neutralizing activity that binds across two E proteins in a virus, wherein the binding across two E proteins comprises binding to DI and the hinge between DI and II on one E protein and DIII of a neighboring E protein, wherein the antibody or fragment thereof binds to amino acids T51, G159, T160, T165, P166, Q167, E172, 1173, and T275 of SEQ ID NO:33 in DI, amino acids N52 and G274 of SEQ ID NO:33 in DII, and K310 of SEQ ID NO:33 in DIII, and
A method of treating a Dengue virus serotype 1 infection comprising administration to a subject of an amount of an isolated antibody effective to reduce or prevent the Dengue virus infection, wherein the antibody comprises a heavy chain sequence comprising the CDR sequences SYGMH (amino acid residues 31-35 of SEQ ID NO:20), VIWYDGSKTYYGDSVKG (amino acid residues 50-66 of SEQ ID NO:20), and GIAGGWAFW (amino acid residues 99-107 of SEQ ID NO:20), and a light chain sequence comprising the CDR sequences RASQNVYSYLG (amino acid residues 24-34 of SEQ ID NO:27), GVTSRAT (amino acid residues 50-56 of SEQ ID NO:27), and QQYAG (amino acid residues 89-93 of SEQ ID NO:27).
A method of treating a Dengue virus serotype 1 infection comprising administration to a subject of an amount of an isolated antibody effective to reduce or prevent the Dengue virus infection, wherein the antibody comprises a heavy chain sequence comprising SEQ ID NO:20 and a light chain sequence comprising SEQ ID NO:27.
Dependencies are inferred from the claim text.